Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial — Thomas Yau (2025) | RDL Network
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Peter R. Galle, Thomas Decaens, Masatoshi Kudo, Shukui Qin, Leonardo Goliatt, Bruno Sangro, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Qi Wang, Caitlyn Stromko, Joseph Hreiki, Thomas Yau
Masatoshi Kudo, Thomas Yau, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Nan Hu, Maria Jesus Jimenez Exposito, Caitlyn Stromko, Peter R. Galle
Thomas Yau, Joong‐Won Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Éric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou‐Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic,
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, В. В. Бредер
Discussion(0)
No comments yet. Be the first to comment.